# Labcorp Agrees to Buy Myriad Genetics Prenatal Business for More Than $210 Million By John Kim Canonical URL: https://www.tokenpost.com/news/business/36029 Published: 2026-10-20T22:15:35.000Z Updated: 2026-10-20T22:15:35.000Z Section: Business > Myriad shares rose more than 20% in premarket trading Oct. 20, the day the companies announced the agreement. Labcorp has agreed to acquire Myriad Genetics’ prenatal health testing business for more than $210 million in cash, adding a second acquisition agreement to its diagnostics business within days. The companies announced the transaction Oct. 20. Myriad shares gained more than 20% in premarket trading that day. The agreement follows a separate Labcorp transaction announced Oct. 15. In that deal, Labcorp agreed to [buy selected BioReference Health assets](), including more than 80 patient service centers and the 4Kscore Test. A revenue-based adjustment could change the $722 million cash payment Labcorp is due to make at closing. The BioReference agreement also provides for a possible earnout of up to $150 million based on revenue from the 4Kscore Test. The 4Kscore blood test gauges the risk of aggressive prostate cancer as a patient considers a biopsy. Labcorp expects those assets to generate about $250 million in revenue in their first year after closing. ## Links in this article - [buy selected BioReference Health assets](https://www.tokenpost.com/news/business/32593)